Cullinan Therapeutics, Inc. (CGEM) AI-Powered Stock Analysis
See how Cullinan Therapeutics, Inc. scores across key metrics like financial growth, valuation, and market position using AI-driven evaluation.
CGEM●NASDAQ
HealthcareMedical - Pharmaceuticals
$13.51
$0.92(6.38%)
U.S. Market opens in 43h 12m
Advertisement
Cullinan Therapeutics, Inc. (CGEM)
Model Information
The AI Stock Analysis Model is provided for informational purposes only and should not be considered financial advice. We are continously improving this model to increase accuracy and performance.Read our Full DisclaimerCullinan Therapeutics, Inc. (CGEM) Stock Overall Grade
Cullinan Therapeutics, Inc.’s grade based on a comprehensive AI analysis of financial metrics, growth potential, and market position.
Z
Grade Breakdown by Metric
See how each financial and market factor contributes to Cullinan Therapeutics, Inc.'s overall stock rating.
Forecast
C+Score
56/100Financial Growth
CScore
40/100Fundamental Growth
CScore
41/100Key Ratios
C+Score
55/100Sector Comparison
B+Score
75/100Industry Comparison
C+Score
50/100S&P 500 Benchmark
A+Score
99/100Analyst Consensus
B+Score
75/100Cullinan Therapeutics, Inc. (CGEM) AI-Powered Stock Analysis
This asset demonstrates Good performance with an overall Forecast Score of 56/100 (C+), reflecting weak confidence in its potential. Financial Growth (40/100, C) and Fundamental Growth (41/100, C) highlight its stability, while Key Ratios (55/100, C+) and Sector Comparison (75/100, B+) indicate solid positioning. Compared to broader benchmarks like the S&P 500 (99/100, A+), it shows competitive strength. Analyst Consensus (75/100,B+) suggests High divergence in outlook.Component Analysis Explained
Understand the key factors behind each Cullinan Therapeutics, Inc. stock grade, including financials, comparisons, and forecasts.